CAMBRIDGE, Mass., Jan. 2, 2024
/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq:
NRBO), a clinical-stage biotechnology company focused on
transforming cardiometabolic diseases, today announced
participation in the following industry and investor conferences in
January:
- January 4-6: NASH-TAG
Conference 2024. As a corporate sponsor of this event,
Hyung Heon Kim, President and Chief
Executive Officer and Robert
Homolka, Senior Vice President of Clinical Operations, will
participate, virtually, in this conference designed to bring
together clinicians and researchers in academia and the
pharmaceutical industry for a focused interactive educational
update highlighting the most relevant advances and challenges in
the diagnosis and therapy of NASH and liver fibrosis.
- January 16-17: Biotech
Showcase™. Mr. Kim, Mr. Homolka and Marshall H. Woodworth, Acting Chief Financial
Officer, will participate in virtual one-on-ones with investors and
business development meetings with biopharmaceutical executives.
Interested parties can register through the Biotech Showcase
partneringONE® platform:
https://partneringone.informaconnect.com/sign-in
To schedule a meeting with management of NeuroBo Pharmaceuticals
outside of either conference, please contact Michael Miller at mmiller@rxir.com.
About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals,
Inc. is a clinical-stage biotechnology company focused on
transforming cardiometabolic diseases. The company is currently
developing DA-1241 for the treatment of Metabolic
Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes
Mellitus (T2DM), and is developing DA-1726 for the treatment of
obesity. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119)
agonist that promotes the release of key gut peptides GLP-1, GIP,
and PYY. In preclinical studies, DA-1241 demonstrated a positive
effect on liver inflammation, lipid metabolism, weight loss, and
glucose metabolism, reducing hepatic steatosis, hepatic
inflammation, and liver fibrosis, while also improving glucose
control. DA-1726 is a novel, dual oxyntomodulin (OXM) analog that
functions as a glucagon-like peptide-1 receptor (GLP1R) and
glucagon receptor (GCGR) for the treatment of obesity. OXM is a
naturally-occurring gut hormone that activates GLP1R and GCGR,
thereby decreasing food intake while increasing energy expenditure,
thus potentially resulting in superior body weight loss compared to
selective GLP1R agonists.
For more information, please visit www.neurobopharma.com.
Contacts:
NeuroBo Pharmaceuticals
Marshall H. Woodworth
Interim Chief Financial Officer
+1-857-299-1033
marshall.woodworth@neurobopharma.com
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original
content:https://www.prnewswire.com/news-releases/neurobo-to-participate-in-industry-and-investor-conferences-in-january-302023941.html
SOURCE NeuroBo Pharmaceuticals, Inc.